Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 3,288 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of Castle Biosciences stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $33.64, for a total transaction of $110,608.32. Following the completion of the sale, the insider owned 48,719 shares of the company’s stock, valued at $1,638,907.16. This represents a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 2.1%

NASDAQ CSTL opened at $33.80 on Friday. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The business’s fifty day moving average price is $33.56 and its 200-day moving average price is $26.82.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. As a group, research analysts anticipate that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. NFSG Corp purchased a new position in shares of Castle Biosciences during the 3rd quarter valued at about $36,000. Green Alpha Advisors LLC increased its holdings in Castle Biosciences by 39.1% in the 3rd quarter. Green Alpha Advisors LLC now owns 13,828 shares of the company’s stock worth $491,000 after acquiring an additional 3,887 shares in the last quarter. Tidal Investments LLC purchased a new stake in Castle Biosciences in the 2nd quarter worth approximately $529,000. Engineers Gate Manager LP increased its holdings in Castle Biosciences by 61.5% in the 2nd quarter. Engineers Gate Manager LP now owns 29,480 shares of the company’s stock worth $703,000 after acquiring an additional 11,224 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in Castle Biosciences during the 2nd quarter worth approximately $3,395,000. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CSTL. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research report on Friday, July 31st. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Roth Capital assumed coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective for the company. Wall Street Zen raised shares of Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 26th. Finally, BTIG Research upped their price objective on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management.

The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma.